These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32386438)

  • 21. Histologic features of long-lasting chilblain-like lesions in a paediatric COVID-19 patient.
    Locatelli AG; Robustelli Test E; Vezzoli P; Carugno A; Moggio E; Consonni L; Gianatti A; Sena P
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e365-e368. PubMed ID: 32386459
    [No Abstract]   [Full Text] [Related]  

  • 22. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.
    Zhang X; Song K; Tong F; Fei M; Guo H; Lu Z; Wang J; Zheng C
    Blood Adv; 2020 Apr; 4(7):1307-1310. PubMed ID: 32243501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 and sickle cell disease.
    Menapace LA; Thein SL
    Haematologica; 2020 Nov; 105(11):2501-2504. PubMed ID: 33131239
    [No Abstract]   [Full Text] [Related]  

  • 24. COVID-19 in a Patient With Rheumatoid Arthritis During Tocilizumab Treatment.
    Yamada Z; Nanki T
    J Clin Rheumatol; 2020 Sep; 26(6):240-241. PubMed ID: 32732527
    [No Abstract]   [Full Text] [Related]  

  • 25. Did Whatsapp
    Duong TA; Velter C; Rybojad M; Comte C; Bagot M; Sulimovic L; Bouaziz JD
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e348-e350. PubMed ID: 32330322
    [No Abstract]   [Full Text] [Related]  

  • 26. Lack of tocilizumab effect on mortality in COVID19 patients.
    Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
    Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acral cutaneous lesions in the time of COVID-19.
    Recalcati S; Barbagallo T; Frasin LA; Prestinari F; Cogliardi A; Provero MC; Dainese E; Vanzati A; Fantini F
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e346-e347. PubMed ID: 32330324
    [No Abstract]   [Full Text] [Related]  

  • 28. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Ranger A; Haji R; Kaczmarski R; Danga A
    Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
    [No Abstract]   [Full Text] [Related]  

  • 29. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome.
    Tammaro A; Adebanjo GAR; Parisella FR; Pezzuto A; Rello J
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e306-e307. PubMed ID: 32330340
    [No Abstract]   [Full Text] [Related]  

  • 30. Sudden severe thrombocytopenia in a patient in the recovery stage of COVID-19.
    Chen W; Yang B; Li Z; Wang P; Chen Y; Zhou H
    Lancet Haematol; 2020 Aug; 7(8):e624. PubMed ID: 32464105
    [No Abstract]   [Full Text] [Related]  

  • 31. Cutaneous manifestations in COVID-19: a first perspective.
    Recalcati S
    J Eur Acad Dermatol Venereol; 2020 May; 34(5):e212-e213. PubMed ID: 32215952
    [No Abstract]   [Full Text] [Related]  

  • 32. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients.
    Piccolo V; Neri I; Filippeschi C; Oranges T; Argenziano G; Battarra VC; Berti S; Manunza F; Fortina AB; Di Lernia V; Boccaletti V; De Bernardis G; Brunetti B; Mazzatenta C; Bassi A
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e291-e293. PubMed ID: 32330334
    [No Abstract]   [Full Text] [Related]  

  • 33. Active implications for dermatologists in 'SARS-CoV-2 ERA': Personal experience and review of literature.
    Campanati A; Brisigotti V; Diotallevi F; D'Agostino GM; Paolinelli M; Radi G; Rizzetto G; Sapigni C; Tagliati C; Offidani A
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1626-1632. PubMed ID: 32426855
    [No Abstract]   [Full Text] [Related]  

  • 34. COVID-19-induced atypical pulmonary lymphocytes.
    Vergé V; Soufan R
    Blood; 2020 Nov; 136(19):2241. PubMed ID: 33152090
    [No Abstract]   [Full Text] [Related]  

  • 35. SARS-CoV-2 infection presenting as a febrile rash.
    Amatore F; Macagno N; Mailhe M; Demarez B; Gaudy-Marqueste C; Grob JJ; Raoult D; Brouqui P; Richard MA
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e304-e306. PubMed ID: 32330336
    [No Abstract]   [Full Text] [Related]  

  • 36. Radiotherapy in the era of COVID-19.
    Lancia A; Bonzano E; Bottero M; Camici M; Catellani F; Ingrosso G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):625-627. PubMed ID: 32552073
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment considerations for patients with pemphigus during the COVID-19 pandemic.
    Shakshouk H; Daneshpazhooh M; Murrell DF; Lehman JS
    J Am Acad Dermatol; 2020 Jun; 82(6):e235-e236. PubMed ID: 32283243
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19-associated delayed posthypoxic necrotizing leukoencephalopathy.
    Radmanesh A; Derman A; Ishida K
    J Neurol Sci; 2020 Aug; 415():116945. PubMed ID: 32480073
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.
    Papadavid E; Scarisbrick J; Ortiz Romero P; Guaglino P; Vermeer M; Knobler R; Stadler R; Bagot M
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1633-1636. PubMed ID: 32416629
    [No Abstract]   [Full Text] [Related]  

  • 40. European Task Force on Contact Dermatitis statement on coronavirus disease-19 (COVID-19) outbreak and the risk of adverse cutaneous reactions.
    Balato A; Ayala F; Bruze M; Crepy MN; Gonçalo M; Johansen J; John SM; Pigatto P; Raimondo A; Rustemeyer T; Schuttelaar MA; Svedman C; Aerts O; Uter W; Wilkinson M; Gimenez-Arnau A
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e353-e354. PubMed ID: 32356382
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.